Zydus Lifesciences Alert: HOLD Rating Holds, Target Price Adjusted! What ICICI Securities Says Next?

RESEARCH-REPORTS
Whalesbook Logo
AuthorAbhay Singh|Published at:
Zydus Lifesciences Alert: HOLD Rating Holds, Target Price Adjusted! What ICICI Securities Says Next?
Overview

ICICI Securities' research report indicates Zydus Lifesciences' Q2FY26 revenue beat, driven by consumer wellness and medtech acquisitions. However, subdued margins from these segments and lower gRevlimid revenue impacted EBITDA. The brokerage maintains a HOLD rating with a revised target price of INR 900, citing crucial upcoming litigation outcomes and integration challenges, while retaining FY26 EBITDA margin guidance.

ICICI Securities released a research report on Zydus Lifesciences, noting a revenue beat in Q2FY26 primarily due to recent acquisitions in the consumer wellness and medtech divisions. Despite this revenue growth, the EBITDA margin saw a decline, down 28 basis points year-on-year and 426 basis points quarter-on-quarter. This margin pressure is attributed to the inherently lower margins of the acquired businesses and a reduction in revenue from gRevlimid.

The report highlights that the exclusivity period for gRevlimid is nearing its end. A significant future catalyst is the potential outcome of the Mirabegron litigation, expected in February 2026, which could be crucial for the company. Zydus Lifesciences' domestic business continues to grow in line with market trends, a performance expected to be maintained.

The integration of the medtech and consumer businesses might affect margins in the near term, though the management has reiterated its EBITDA margin guidance of approximately 26% for FY26. Analysts have slightly increased FY26 and FY27 earnings estimates by about 2-3% to account for higher sales from the recent acquisitions. Consequently, the brokerage firm has maintained its HOLD recommendation on the stock, with a revised target price of INR 900 (down from INR 910), based on a price-to-earnings multiple of 22 times FY27 estimated earnings.

Impact
This research report from ICICI Securities provides investors with a detailed outlook on Zydus Lifesciences' performance and strategic direction. The maintained HOLD rating and adjusted target price offer guidance for current shareholders and potential investors, influencing trading decisions based on the analysis of revenue drivers, margin pressures, and key litigation outcomes. The report directly impacts investor sentiment and the stock's near-term price action. Rating: 7/10

Difficult Terms:
EBITDA Margin: Earnings Before Interest, Taxes, Depreciation, and Amortization margin, a key indicator of a company's operating profitability.
gRevlimid: Refers to the generic version of the drug Revlimid, used in treating certain cancers.
Mirabegron: A medication used to treat overactive bladder.
FY26/27E: Fiscal Year 2026/2027 Estimates, referring to projected financial performance for those years.
EPS: Earnings Per Share, which indicates the portion of a company's profit allocated to each outstanding share of common stock.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.